J&J Eyes Restructured Device Biz As New CEO Gorsky Steps In
This article was originally published in The Gray Sheet
Executive Summary
Big changes are underway at J&J. In April, Alex Gorsky will become the company’s new CEO. And the firm plans a restructuring of its device business upon completion of its $20 billion-plus Synthes acquisition in the first half of the year.
You may also be interested in...
Johnson & Johnson CEO Gorsky Reaffirms Diversified Strategy
Faced with spin-off models from other diversified health care firms, including Abbott and Pfizer, Gorsky defended J&J’s broader-based approach as a better long-term strategy.
J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.
J&J’s Sedasys Sedation System Now “Approvable,” Though Some Questions Remain
Outstanding FDA questions pertain to follow-up data, user training and “post-market observance and those sorts of things,” CFO Dominic Caruso told investors during the firm’s first-quarter earnings call April 17.